AnGes, Inc.
JPX: 4563.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ei Yamada
- Employees
- 55
- Headquarters
- Ibaraki, Japan
- IPO year
- 2002
- Market cap
- ¥21B
- Website
- https://www.anges.co.jp
Loading 4563…
Loading profile data…Frequently asked questions about 4563
What does AnGes, Inc. (4563.T) do?
AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of critical limb ischemia, a serious impairment of blood circulation in the leg. The company is also developing NF-kB Decoy Oligonucleotide,...
Where does 4563.T trade?
AnGes, Inc. (4563.T) trades on the Tokyo Stock Exchange.
What sector is 4563.T in?
AnGes, Inc. (4563.T) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of AnGes, Inc.?
Ei Yamada is the chief executive officer of AnGes, Inc. (4563.T).
Where is AnGes, Inc. headquartered?
AnGes, Inc. is headquartered in Japan.
Does 4563.T pay a dividend?
AnGes, Inc. (4563.T) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4563.T go public?
AnGes, Inc. (4563.T) completed its initial public offering in 2002.